CFDE Data Portal | Search PIAS1

	Label	Description
	PIAS1 Gene (Entity type)	ENSG00000033800 - protein inhibitor of activated STAT 1
	PIAS1 associations Collection (Entity type)	Associations for PIAS1_associations
	PIAS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	PIAS1 MOUSE Protein (Entity type)	E3 SUMO-protein ligase PIAS1
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE148200 0 V 2 GEMCITABINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876,GSE147877 2 V 7 ENZALUTAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS

PIAS1

ENSG00000033800 - protein inhibitor of activated STAT 1

PIAS1 associations

Associations for PIAS1_associations

PIAS1 associations.tsv

A file from IDG as part of the Harmonizome project

PIAS1 MOUSE

E3 SUMO-protein ligase PIAS1

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE203362 0 V 1 ENZALUTAMIDE HUMAN DN

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE148200 0 V 2 GEMCITABINE HUMAN UP

A Gene Set from LINCS

GSE147876,GSE147877 2 V 7 ENZALUTAMIDE HUMAN UP

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 10 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.